GLAX B05 1993-213779/26 =RU 2129424-C1

Surfactant free aerosol formulation for treatment of e.g. asthma - uses ozone-friendly fluorocarbon or hydrogen contg. chloro-fluorocarbon propellant

GLAXO GROUP LTD 1992.02.06 1992GB-002522 (1991.12.12 1991GB-026378)

(1999.04.27) *WO 9311743-A1 *A61K 9/12, 31/56*

1992.12.04 1994RU-030722 1992.12.04 1992WO-EP02808 Based on WO9311743-A (Eng)

Addnl.Data: 1991.12.12 1991GB-026405

1993-213780/26 1993-213781/26

Formulation comprises a particulate medicament (I) e.g. salmeterol, salbutamol, fluticasone propionate, becolomethasone dipropionate and a fluorocarbon or hydrogen-contg chlorofluorocarbon propellant.

Also claimed are the prepn of the surface-modified medicament and a canister for delivering metered doses of the aerosol formulation.

Pref., (I) is salmeterol xinafoate (Ia); salbutamol sulphate; fluticascone propionate; beclomethasone dipropionate; or a combination of salmeterol xinafoate and fluticasone propionate; or salbutamol and beclomethasone dipropionate. The propellant is pref. 1,1,1,2-tetrafluoroethane (II). (I) is present in an amt. of 0.005-10% wt. based on the total wt. of the formulation e.g. a salbutamol salt and 1,1,1,2-tetrafluoroethane in a ratio of 0.05:18 by wt. Surface-modified (I) are prepd. by admixture of particulate (I) with a non-polar, non-solvent liq. followed by removal of the lid.

USE/ADVANTAGE - The aerosol formulations are 'ozone friendly' using H-contg. chlorofluorocarbons as propellants and having no requirement for added surfactants or solvents for stabilising the constituent medicament(s). (I) can be used separately or in combination and may be e.g. analgesics, antiallergics, anti-infectives, antihistamines, anti-inflammatories, bronchodilators, diueretics, hormones, or therapeutic proteins and peptides. Admin. is by inhalation. Dosage of (I) is 50-2000 micro-g per day.

© 2000 Derwent Information
14 Great Queen Street LondonWC2B 5DF England UK
Derw nt Information
1725 Duke Street Suite 250 Alexandria VA 22314 USA